FDA Approves Rezdiffra, First Specific Treatment for Nonalcoholic Steatohepatitis
By Physician’s Briefing Staff HealthDay Reporter
FRIDAY, March 15, 2024 -- On Thursday, the U.S. Food and Drug Administration announced the approval of Rezdiffra (resmetirom) to treat noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced fibrosis.
"Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage," Nikolay Nikolov, M.D., acting director of the Office of Immunology and Inflammation in the FDA Center for Drug Evaluation and Research, said in an agency news release. "Today's approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise."
The FDA said that the drug was approved under an "accelerated" pathway because it addressed "an unmet medical need."
Rezdiffra was approved based on data collected after a year as part of an ongoing 54-month trial. Those data assessed improvement in levels of liver scarring compared to patients who were taking a placebo. Between 24 and 36 percent of NASH patients taking 100 mg of Rezdiffra saw their NASH resolve and experienced no worsening of liver scarring, compared to 9 to 13 percent of those who received placebo, the FDA said. A similar ratio saw their NASH continuing but experienced no worsening of liver scarring, the agency said.
Side effects of Rezdiffra include diarrhea and nausea, and its label includes warnings regarding a risk for drug-induced liver toxicity and gallbladder issues. Rezdiffra should not be taken by patients with decompensated cirrhosis, the FDA said, and the drug may interact with statins.
The approval of Rezdiffra was granted to Madrigal Pharmaceuticals.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter...
GLP-1 RA Reduces Severity of Steatotic Liver Disease in People With HIV
MONDAY, March 18, 2024 -- For people with HIV (PWH) with metabolic-associated steatotic liver disease (MASLD), semaglutide is associated with absolute and relative declines in...
NASH Resolution Increased, Improvement of Fibrosis Seen With Resmetirom
THURSDAY, Feb. 8, 2024 -- For patients with nonalcoholic steatohepatitis (NASH) and fibrosis stage F1B, F2, or F3, 80- and 100-mg resmetirom is better than placebo, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.